LEUVEN, Belgium, June 26, 2015 (GLOBE NEWSWIRE) -- Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor. Oncurious is a new oncology company and a joint venture between ThromboGenics NV and VIB, a leading life sciences institute in Flanders (Belgium).
Since 15 years Prof Carmeliet (VIB Vesalius Research Center, KU Leuven) has focused his research interests on unravelling the molecular basis ofhas focused since 15 years its research interests on unraveling the molecular basis of neuro-vascular biological processes and diseases, and translating these genetic insights in therapeutic concepts - with the ultimate aspiration to develop novel treatmentsThe Vesalius Research Center (VRC) has focused since 15 years its research interests on unraveling the molecular basis of neuro-vascular biological processes and diseases, and translating these genetic insights in therapeutic concepts - with the ultimate aspiration to develop novel treatments neuro-vascular biological processes and diseases, and translating these genetic insights into therapeutic concepts - with the ultimate aspiration to develop novel treatments.
Research conducted by Prof Carmeliet's team at VIB/KU Leuven, in collaboration with Prof Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston), generated the first pre-clinical data on the use of human monoclonal antibodies against placental growth factor (PlGF) in the treatment of medulloblastoma. Based on the positive results, TB-403 will be now further developed by Oncurious for the treatment of pediatric tumors.
Prof Dr Peter Carmeliet comments: "I am pleased with this opportunity to support the translation of pre-clinical research conducted at VIB/KU Leuven and other world leading institutes into potential novel cancer treatments. Working with Oncurious NV gives me the occasion to remain very closely involved in the process of developing a drug for clinical use."
Dr Patrik De Haes, CEO of ThromboGenics NV and Executive Chairman of Oncurious NV: We are delighted that Prof Carmeliet has accepted the role of Chief Scientific Strategy Advisor with Oncurious. Professor Carmeliet is a globally renowned leader in the field of oncology research and its underlying biological processes. His scientific insights, research and in-depth expertise will be very valuable as the Oncurious team progresses its current clinical development of TB-403 for the treatment of pediatric brain tumors, I am confident that his insights will, in time, allow Oncurious to build an oncology pipeline and become an international leader in developing novel cancer therapies."
For further information please contact:
| Oncurious NV / ThromboGenics NV: Wouter Piepers |
+32 16 75 13 10 / +32 478 33 56 32
VIB/ KU Leuven :
| Citigate Dewe Rogerson |
David Dible/Malcolm Robertson
Tel: +44 20 7638 9571
About Oncurious NV
Oncurious NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors. Oncurious is a joint venture between ThromboGenics and VIB, a leading life science research institute in Flanders (Belgium).
Oncurious plans to initiate a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. Enrolment of the first patient is expected by the end of 2015.
BioInvent International is Oncurious' co-development partner for the planned Phase I/IIa TB-403 clinical trial.
More information on Oncurious can be found at www.oncurious.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.